DK3212230T3 - Dosering og indgivelse af ikke-fucosylerede anti-CD40-antistoffer - Google Patents

Dosering og indgivelse af ikke-fucosylerede anti-CD40-antistoffer Download PDF

Info

Publication number
DK3212230T3
DK3212230T3 DK15854895.8T DK15854895T DK3212230T3 DK 3212230 T3 DK3212230 T3 DK 3212230T3 DK 15854895 T DK15854895 T DK 15854895T DK 3212230 T3 DK3212230 T3 DK 3212230T3
Authority
DK
Denmark
Prior art keywords
antibodies
dosage
administration
fucosylated anti
fucosylated
Prior art date
Application number
DK15854895.8T
Other languages
English (en)
Inventor
Che-Leung Law
Stanford Peng
Jing Yang
Haley Neff-Laford
Shyra Gardai
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55858352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3212230(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seagen Inc filed Critical Seagen Inc
Application granted granted Critical
Publication of DK3212230T3 publication Critical patent/DK3212230T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0009—Making of catheters or other medical or surgical tubes
    • A61M25/0012—Making of catheters or other medical or surgical tubes with embedded structures, e.g. coils, braids, meshes, strands or radiopaque coils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0017—Catheters; Hollow probes specially adapted for long-term hygiene care, e.g. urethral or indwelling catheters to prevent infections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/002—Packages specially adapted therefor ; catheter kit packages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK15854895.8T 2014-10-29 2015-10-29 Dosering og indgivelse af ikke-fucosylerede anti-CD40-antistoffer DK3212230T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072031P 2014-10-29 2014-10-29
US201562134955P 2015-03-18 2015-03-18
PCT/US2015/058108 WO2016069919A1 (en) 2014-10-29 2015-10-29 Dosage and administration of non-fucosylated anti-cd40 antibodies

Publications (1)

Publication Number Publication Date
DK3212230T3 true DK3212230T3 (da) 2021-04-19

Family

ID=55858352

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15854895.8T DK3212230T3 (da) 2014-10-29 2015-10-29 Dosering og indgivelse af ikke-fucosylerede anti-CD40-antistoffer

Country Status (22)

Country Link
US (8) US11213584B2 (da)
EP (2) EP3831847A1 (da)
JP (5) JP6691113B2 (da)
KR (1) KR20170072884A (da)
CN (2) CN114522228A (da)
AU (2) AU2015339128C1 (da)
BR (1) BR112017008959A2 (da)
CA (1) CA2963720A1 (da)
CY (1) CY1124033T1 (da)
DK (1) DK3212230T3 (da)
EA (1) EA036498B1 (da)
ES (1) ES2864756T3 (da)
HK (1) HK1243328A1 (da)
HU (1) HUE054075T2 (da)
IL (2) IL299075A (da)
MX (1) MX2017005152A (da)
PL (1) PL3212230T3 (da)
PT (1) PT3212230T (da)
SG (2) SG10201913099YA (da)
SI (1) SI3212230T1 (da)
WO (1) WO2016069919A1 (da)
ZA (2) ZA201702347B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6691113B2 (ja) * 2014-10-29 2020-04-28 シアトル ジェネティックス， インコーポレイテッド 非フコシル化抗ｃｄ４０抗体の投与量および投与
US20210001032A1 (en) * 2015-03-27 2021-01-07 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
WO2017143069A1 (en) 2016-02-17 2017-08-24 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
SG10201914132RA (en) 2016-05-27 2020-03-30 Abbvie Biotherapeutics Inc Anti-cd40 antibodies and their uses
TW201806972A (zh) 2016-05-27 2018-03-01 美商艾伯維生物醫療股份有限公司 雙特異性結合蛋白
WO2018088850A2 (ko) 2016-11-11 2018-05-17 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
JP7391845B2 (ja) 2017-12-01 2023-12-05 シージェン インコーポレイテッド Ｃｄ４７抗体及びがんを治療するためのその使用
WO2019178236A1 (en) * 2018-03-13 2019-09-19 Biothera Pharmaceuticals, Inc. Beta glucan and cd40 agonist combination immunotherapy
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
CN113226357A (zh) 2018-11-23 2021-08-06 斯特赖克药物公司 双特异性缀合物
FR3089597B1 (fr) 2018-12-06 2020-11-20 Gaztransport Et Technigaz Cuve étanche et thermiquement isolante
MX2021007327A (es) * 2018-12-19 2021-09-08 Seagen Inc Fucosilacion controlada de anticuerpos.
US20220151983A1 (en) * 2019-03-18 2022-05-19 Score Pharma, Inc. Compounds for inhibiting fucosylation and methods for using the same
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2022536982A (ja) * 2019-06-21 2022-08-22 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 癌およびその他の疾患の処置のためのα３β１インテグリンの標的化
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2022006179A1 (en) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022072523A1 (en) 2020-09-30 2022-04-07 Seagen Inc. Uveal melanoma treatment using sea-cd40
MX2023004941A (es) 2020-11-08 2023-07-12 Seagen Inc Conjugado de anticuerpo y fármaco para terapia de combinación con inhibidor de células inmunitarias.
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4347657A1 (en) 2021-05-25 2024-04-10 Seagen Inc. Methods of quantifying anti-cd40 antibodies
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023010080A1 (en) 2021-07-30 2023-02-02 Seagen Inc. Treatment for cancer
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001016180A2 (en) 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
ATE363290T1 (de) 1999-10-04 2007-06-15 Novartis Vaccines & Diagnostic Cd40 antagonist zur behandlung von psoriasis
MXPA02010147A (es) 2000-04-19 2003-10-15 Tanox Inc Antagonistas cd40 para uso en el tratamiento de psoriasis y otras condiciones inflamatorias de la piel.
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
AU2001296507A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anti-cd40 monoclonal antibody
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2006128103A2 (en) 2005-05-26 2006-11-30 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
US20090304687A1 (en) * 2005-12-09 2009-12-10 Seattle Genetics , Inc. Methods of using cd40 binding agents
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
AU2008323701B2 (en) 2007-11-07 2015-03-26 Genentech, Inc Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
US8551485B2 (en) 2008-01-23 2013-10-08 Xencor, Inc. Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells
JP5624535B2 (ja) * 2008-05-02 2014-11-12 シアトル ジェネティクス，インコーポレーテッド 低いコアフコシル化を有する抗体及び抗体誘導体を調製するための方法並びに組成物
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013043569A1 (en) * 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JP6691113B2 (ja) * 2014-10-29 2020-04-28 シアトル ジェネティックス， インコーポレイテッド 非フコシル化抗ｃｄ４０抗体の投与量および投与

Also Published As

Publication number Publication date
JP2021088609A (ja) 2021-06-10
US11202827B2 (en) 2021-12-21
AU2015339128C1 (en) 2021-12-16
CN107073118A (zh) 2017-08-18
MX2017005152A (es) 2017-08-04
SG11201702598XA (en) 2017-05-30
IL251552B2 (en) 2023-05-01
US20220249662A1 (en) 2022-08-11
AU2015339128A1 (en) 2017-04-20
US20240075134A1 (en) 2024-03-07
AU2015339128B2 (en) 2021-01-21
US20230201344A1 (en) 2023-06-29
HUE054075T2 (hu) 2021-08-30
IL251552B1 (en) 2023-01-01
BR112017008959A2 (pt) 2018-01-16
ES2864756T3 (es) 2021-10-14
CN114522228A (zh) 2022-05-24
CY1124033T1 (el) 2022-05-27
EP3212230A4 (en) 2018-06-20
JP7165166B2 (ja) 2022-11-02
PL3212230T3 (pl) 2021-07-26
JP2017533909A (ja) 2017-11-16
KR20170072884A (ko) 2017-06-27
IL251552A0 (en) 2017-05-29
US20170333556A1 (en) 2017-11-23
PT3212230T (pt) 2021-04-19
EA201790932A1 (ru) 2017-08-31
EA036498B1 (ru) 2020-11-17
ZA202102219B (en) 2022-10-26
US20240075135A1 (en) 2024-03-07
JP2023126406A (ja) 2023-09-07
US20220265822A1 (en) 2022-08-25
JP2020050677A (ja) 2020-04-02
IL299075A (en) 2023-02-01
ZA201702347B (en) 2021-07-28
SG10201913099YA (en) 2020-02-27
US20170137528A1 (en) 2017-05-18
US20230201343A1 (en) 2023-06-29
HK1243328A1 (zh) 2018-07-13
EP3212230B1 (en) 2021-01-20
JP6691113B2 (ja) 2020-04-28
US11213584B2 (en) 2022-01-04
CA2963720A1 (en) 2016-05-06
WO2016069919A1 (en) 2016-05-06
AU2021202407A1 (en) 2021-05-20
SI3212230T1 (sl) 2021-08-31
JP2020200343A (ja) 2020-12-17
EP3212230A1 (en) 2017-09-06
CN107073118B (zh) 2022-03-01
JP6833080B2 (ja) 2021-02-24
EP3831847A1 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
DK3212230T3 (da) Dosering og indgivelse af ikke-fucosylerede anti-CD40-antistoffer
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3303395T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3827845T3 (da) Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
DK3463248T3 (da) Anordnnger til anvendelse af lægemiddelanordninger
DK3244948T3 (da) Bestemmelse af medikamentdosis
DK3126394T3 (da) Anti-OX40-antistoffer og fremgangsmåder til anvendelse
DK3230319T3 (da) Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
DK3262071T3 (da) Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
DK3129018T3 (da) Behandling af NAFLD og NASH
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3178849T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK3218828T3 (da) Dataindsamling til dosering af lægemidler
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3204398T3 (da) Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3099356T3 (da) Medikamentadministrationsanordning
DK3237054T3 (da) Indretning til fremstilling og påføring af en medicinsk substans
DK3569166T3 (da) Indretning til akut behandling af hjertestop
DK3160521T3 (da) Prøvetagningsanordning til bestemmelse af mængde og indgivet lægemiddeldosis og tilhørende fremgangsmåder
DK3237621T3 (da) Varianter af human alpha-galactosidase